Danaher Co. (NYSE:DHR – Free Report) – Analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Danaher in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst P. Souda now forecasts that the conglomerate will post earnings of $1.63 per share for the quarter, down from their previous forecast of $2.02. The consensus estimate for Danaher’s current full-year earnings is $7.77 per share. Leerink Partnrs also issued estimates for Danaher’s Q4 2025 earnings at $2.43 EPS, FY2025 earnings at $7.65 EPS, Q1 2026 earnings at $1.93 EPS, Q2 2026 earnings at $1.96 EPS, Q3 2026 earnings at $2.05 EPS, Q4 2026 earnings at $2.66 EPS and FY2026 earnings at $8.60 EPS.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm earned $2.09 EPS.
Get Our Latest Analysis on Danaher
Danaher Price Performance
DHR opened at $215.05 on Monday. The business’s 50-day moving average is $234.93 and its two-hundred day moving average is $252.88. Danaher has a 1 year low of $210.04 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The firm has a market capitalization of $155.33 billion, a PE ratio of 40.73, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83.
Danaher Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date was Friday, December 27th. Danaher’s payout ratio is presently 20.45%.
Insider Buying and Selling at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.90% of the stock is currently owned by corporate insiders.
Institutional Trading of Danaher
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wedge Capital Management L L P NC increased its position in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after buying an additional 38 shares in the last quarter. Meridian Financial Partners LLC increased its position in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after buying an additional 40 shares in the last quarter. Kovack Advisors Inc. increased its position in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after buying an additional 41 shares in the last quarter. Well Done LLC increased its position in shares of Danaher by 1.2% in the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after buying an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC increased its position in shares of Danaher by 0.9% in the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after buying an additional 42 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Differences Between Momentum Investing and Long Term Investing
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- What is a support level?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How to Use the MarketBeat Dividend Calculator
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.